CLINICAL TRIALS PROFILE FOR METICORTELONE

All Clinical Trials for Meticortelone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00900445 ↗	Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia	Withdrawn	National Cancer Institute (NCI)		2008-03-24	This clinical trial is studying body mass index in younger patients receiving prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the affect of body mass index on the way anticancer drugs work in the body. It may also help doctors predict how patients will respond to treatment
NCT00900445 ↗	Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia	Withdrawn	Children's Oncology Group		2008-03-24	This clinical trial is studying body mass index in younger patients receiving prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the affect of body mass index on the way anticancer drugs work in the body. It may also help doctors predict how patients will respond to treatment
NCT02828358 ↗	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2017-03-27	This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug may kill more cancer cells.
NCT03007147 ↗	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Recruiting	EsPhALL network I-BFM Study Group	Phase 3	2017-07-28	This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
NCT03007147 ↗	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 3	2017-07-28	This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
NCT03007147 ↗	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Recruiting	Children's Oncology Group	Phase 3	2017-07-28	This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
NCT03914625 ↗	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 3	2019-06-28	This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients with B-ALL. This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens.

Clinical Trial Conditions for Meticortelone

Condition Name

Condition Name for Meticortelone
Intervention	Trials
B Acute Lymphoblastic Leukemia	5
Mixed Phenotype Acute Leukemia	3
Refractory Mixed Phenotype Acute Leukemia	2
Blasts More Than 25 Percent of Bone Marrow Nucleated Cells	2

Condition MeSH

Condition MeSH for Meticortelone
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	8
Leukemia, Lymphoid	8
Leukemia	8
Acute Disease	4

Clinical Trial Locations for Meticortelone

Trials by Country

Trials by Country for Meticortelone
Location	Trials
United States	233
Canada	30
Australia	15
New Zealand	6
Puerto Rico	4

Trials by US State

Trials by US State for Meticortelone
Location	Trials
Texas	6
Tennessee	6
South Carolina	6
Pennsylvania	6
Oklahoma	6

Clinical Trial Progress for Meticortelone

Clinical Trial Phase

Clinical Trial Phase for Meticortelone
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Meticortelone
Clinical Trial Phase	Trials
Recruiting	4
Not yet recruiting	4
Withdrawn	1

Clinical Trial Sponsors for Meticortelone

Sponsor Name

Sponsor Name for Meticortelone
Sponsor	Trials
National Cancer Institute (NCI)	9
Children's Oncology Group	5
EsPhALL network I-BFM Study Group	1

Sponsor Type

Sponsor Type for Meticortelone
Sponsor	Trials
NIH	9
Other	6

Meticortelone: Clinical Trials, Market Analysis, and Projections

Introduction

Meticortelone, also known as prednisolone, is a synthetic steroid that has been widely used in the treatment of various inflammatory and autoimmune conditions. Here, we will delve into the clinical trials, market analysis, and projections for this drug.

Clinical Trials and Efficacy

Early Clinical Trials

In the 1950s, preliminary clinical trials were conducted to evaluate the efficacy of prednisone (the precursor to prednisolone, known as Meticorten) in treating rheumatic diseases. These trials, conducted at the Beth Israel Hospital in New York City, involved patients with active rheumatoid arthritis, disseminated lupus erythematosus, active rheumatic carditis, and acute gouty arthritis. The results showed significant anti-rheumatic, anti-inflammatory, metabolic, and hormonal properties of prednisone, setting the stage for its widespread use[1].

Current Clinical Use

Prednisolone, the active metabolite of prednisone, is now commonly used in various clinical settings, including the treatment of asthma, allergic reactions, and autoimmune diseases. Its efficacy in reducing inflammation and suppressing the immune system has made it a cornerstone in managing chronic conditions.

Market Analysis

Global Corticosteroids Market

The global market for corticosteroids, which includes prednisolone, is substantial and growing. The topical corticosteroids market, for instance, is projected to reach USD 8.19 billion by 2030, growing at a CAGR of 6% from 2021 to 2030. This growth is driven by increasing demand for effective treatments for skin conditions and other inflammatory diseases[5].

Segment Analysis

The corticosteroids market can be segmented by molecule name, medication type, application, and region. Prednisolone, being a widely used corticosteroid, contributes significantly to this market. Its applications span across various therapeutic areas, including respiratory, dermatological, and rheumatological conditions.

Market Projections

Growth Drivers

The market for prednisolone and other corticosteroids is driven by several factors:

• Increasing Prevalence of Chronic Diseases: Conditions such as asthma, rheumatoid arthritis, and skin allergies are on the rise, driving the demand for effective treatments like prednisolone.
• Advancements in Formulations: New formulations and delivery methods, such as topical creams and inhalers, are enhancing the efficacy and patient compliance of corticosteroid treatments.
• Expanding Healthcare Infrastructure: Improving healthcare systems in developing regions are increasing access to these medications, contributing to market growth.

Regional Analysis

The market for corticosteroids, including prednisolone, varies by region:

• North America and Europe: These regions have a high prevalence of chronic inflammatory diseases and well-established healthcare systems, making them significant markets.
• Asia-Pacific: This region is expected to show rapid growth due to increasing healthcare expenditure and a large patient population[5].

Competitive Landscape

Key Players

The market for corticosteroids is competitive, with several key players involved in the manufacture and distribution of prednisolone and other corticosteroids. These companies often engage in strategies such as product launches, expansions, and partnerships to maintain market share.

Challenges and Opportunities

Side Effects and Alternatives

One of the challenges facing the market for prednisolone is the potential for significant side effects, particularly with long-term use. This has led to the development of alternative treatments, such as biologics and targeted therapies, which may reduce the reliance on corticosteroids in some therapeutic areas.

Emerging Markets

Despite the challenges, emerging markets offer significant opportunities for growth. Increasing awareness and access to healthcare in these regions are expected to drive the demand for corticosteroids like prednisolone.

Key Takeaways

• Clinical Efficacy: Prednisolone has been proven effective in treating various inflammatory and autoimmune conditions through numerous clinical trials.
• Market Growth: The global corticosteroids market, including prednisolone, is projected to grow significantly, driven by increasing demand and advancements in formulations.
• Regional Variations: The market is influenced by regional factors such as healthcare infrastructure and disease prevalence.
• Competitive Landscape: The market is competitive, with key players focusing on product innovation and strategic partnerships.

FAQs

What is Meticortelone?

Meticortelone, also known as prednisolone, is a synthetic steroid used to treat various inflammatory and autoimmune conditions.

What were the findings of early clinical trials for Meticortelone?

Early clinical trials showed that prednisone (the precursor to prednisolone) had significant anti-rheumatic, anti-inflammatory, metabolic, and hormonal properties.

What is the projected market size for the global corticosteroids market by 2030?

The global topical corticosteroids market is expected to reach USD 8.19 billion by 2030, growing at a CAGR of 6% from 2021 to 2030.

What are the key drivers of the corticosteroids market?

The market is driven by the increasing prevalence of chronic diseases, advancements in formulations, and expanding healthcare infrastructure.

Which regions are expected to show significant growth in the corticosteroids market?

The Asia-Pacific region is expected to show rapid growth due to increasing healthcare expenditure and a large patient population.

Sources

1. Preliminary Clinical Trials with Prednisone (Meticorten) in Rheumatic Diseases - JAMA Network.
2. Metoprolol Tartrate Market Size Report, 2022-2027 - IndustryARC.
3. NSCLC Market - Global Drug Forecast & Market Analysis to 2025 - GlobalData.
4. A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia - CareAcross.
5. Topical Corticosteroids Market Size, Analysis, Forecasts to 2030 - Spherical Insights.